Erste Asset Management GmbH Purchases Shares of 20,300 Ascendis Pharma A/S (NASDAQ:ASND)

Erste Asset Management GmbH purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 20,300 shares of the biotechnology company's stock, valued at approximately $2,936,000.

A number of other institutional investors also recently bought and sold shares of ASND. Avoro Capital Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after acquiring an additional 229,995 shares during the period. Westfield Capital Management Co. LP grew its holdings in Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock valued at $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock worth $278,760,000 after purchasing an additional 155,971 shares during the period. Fred Alger Management LLC lifted its stake in Ascendis Pharma A/S by 65.0% in the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company's stock worth $41,879,000 after purchasing an additional 120,952 shares during the last quarter. Finally, Tri Locum Partners LP boosted its position in shares of Ascendis Pharma A/S by 102.1% during the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company's stock valued at $31,062,000 after buying an additional 115,092 shares during the period.

Ascendis Pharma A/S Stock Performance

ASND stock traded down $2.16 during trading on Tuesday, hitting $131.35. 237,026 shares of the company's stock traded hands, compared to its average volume of 510,053. Ascendis Pharma A/S has a 1 year low of $101.43 and a 1 year high of $161.00. The business has a fifty day simple moving average of $131.65 and a two-hundred day simple moving average of $132.45.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analysts' expectations of $94.74 million. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company increased their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Wedbush reiterated an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. JPMorgan Chase & Co. lowered their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating for the company in a research note on Wednesday, October 23rd. Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Finally, The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.